Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02088021
NCT02088021WithdrawnNot Applicable

Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access

Abbott Medical Devices0 sitesStarted: January 1, 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Primary Endpoint
Major Vascular Complications related to the Portico ALC Delivery System
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this clinical investigation is to evaluate the use of the Portico ALC Delivery System to place a transcatheter aortic valve through an alternative access site, specifically subclavian/axillary or TAo.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subject has provided written informed consent.
  • •Subject is 65 years of age or older at the time of index procedure, and/or has comorbidities that, in the opinion of the Principal Investigator or the Subject Selection Committee, preclude surgical valve replacement.
  • •Subject's aortic annulus diameter meets the range indicated in the Instructions for Use as measured by multislice CT conducted within 120 days prior to the index procedure.
  • •Subject has senile degenerative aortic stenosis with echocardiography within 30 days of index procedure as defined by at least 1 of the following:
  • •derived mean gradient greater than 40 mmHg, OR
  • •jet velocity greater than 4.0 m/s, OR
  • •aortic valve area of less than 0.8 cm2, OR
  • •aortic valve area index less than or equal to 0.6 cm2/m
  • •Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional Classification of II, III, or IV.
  • •Subject is deemed high operable risk and delivery route is suitable for TAVI per the medical opinion of the Subject Selection Committee.
  • •Subject's predicted operative mortality or serious, irreversible morbidity risk is less than 50% at 30 days post index procedure.

Exclusion Criteria

  • •Subject is unwilling or unable to comply with all study-required follow-up evaluations.
  • •Subject has a documented history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the index procedure.
  • •Subject has carotid artery disease requiring intervention.
  • •Evidence of an acute myocardial infarction (MI) within 30 days prior to patient providing consent (defined as: ST Segment Elevation as evidenced on 12 Lead ECG).
  • •Subject has a native aortic valve that is congenitally unicuspid, bicuspid, quadricuspid or non-calcified as seen by echocardiography.
  • •Subject has mitral valvular regurgitation greater than grade III.
  • •Subject has moderate or severe mitral stenosis.
  • •Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any position.
  • •Subject refuses any blood product transfusion.
  • •Subject refuses surgical valve replacement.
  • •Subject has left ventricular ejection fraction (LVEF) less than 20%.
  • •Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring revascularization.
  • •Subject has had a percutaneous interventional or other invasive cardiovascular or peripheral vascular procedure less than or equal to 14 days of index procedure.
  • •Subject has severe basal septal hypertrophy that would interfere with transcatheter aortic valve placement.
  • •Subject has a history of, or is currently diagnosed with endocarditis.
  • •There is imaging evidence of intracardiac mass, thrombus, or vegetation.
  • •Subject is considered hemodynamically unstable (requiring inotropic support or mechanical heart assistance).
  • •Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to stabilize heart failure.
  • •Subject with significant pulmonary disease as determined and documented by the Investigator.
  • •Subject has significant chronic steroid use as determined and documented by the Investigator.
  • •Subject has a documented hypersensitivity or contraindication to anticoagulant or antiplatelet medication.
  • •Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0 mg/dL (265.5 µmol/L) or end-stage renal disease requiring chronic dialysis.
  • •Subject has morbid obesity defined as a BMI greater than or equal to
  • •Subject has ongoing infection or sepsis.
  • •Subject has blood dyscrasias (eg, leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy).
  • •Subject has a current autoimmune disease that, in the opinion of the Principal Investigator or the Subject Selection Committee, precludes the subject from study participation.
  • •Significant ascending aortic disease documented by diameter greater than 40mm.
  • •Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90 days prior to the index procedure.
  • •Subject is currently participating in another investigational drug or device study.
  • •Subject requires emergency surgery for any reason.
  • •Subject has a life expectancy less than 12 months.
  • •Subject has other medical, social or psychological conditions that, in the opinion of the Principal Investigator or the Subject Selection Committee, preclude the subject from study participation.
  • •Subject is diagnosed with dementia or admitted to a chronic care facility which would fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits.
  • •Subject is unwilling or unable to comply with all study-required follow-up evaluations.
  • •Subject has a documented history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the index procedure.
  • •Subject has carotid artery disease requiring intervention.
  • •Evidence of an acute myocardial infarction (MI) within 30 days prior to patient providing consent (defined as: ST Segment Elevation as evidenced on 12 Lead ECG).
  • •Subject has a native aortic valve that is congenitally unicuspid, bicuspid, quadricuspid or non-calcified as seen by echocardiography.
  • •Subject has mitral valvular regurgitation greater than grade III.
  • •Subject has moderate or severe mitral stenosis.
  • •Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any position.
  • •Subject refuses any blood product transfusion.
  • •Subject refuses surgical valve replacement.
  • •Subject has left ventricular ejection fraction (LVEF) less than 20%.
  • •Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring revascularization.
  • •Cardiovascular or peripheral vascular procedure less than or equal to 14 days of index procedure.
  • •Subject has severe basal septal hypertrophy that would interfere with transcatheter aortic valve placement.
  • •Subject has a history of, or is currently diagnosed with endocarditis.
  • •There is imaging evidence of intracardiac mass, thrombus, or vegetation.
  • •Subject is considered hemodynamically unstable (requiring inotropic support or mechanical heart assistance).
  • +16 more not shown

Arms & Interventions

Portico Transcatheter Aortic Valve Implantation

Experimental

Placement of the SJM Portico aortic valve with a ALC delivery system

Intervention: Portico Transcatheter Aortic Valve (Device)

Outcomes

Primary Outcomes

Major Vascular Complications related to the Portico ALC Delivery System

Time Frame: 30 day post procedure

All cause mortality

Time Frame: 30 day post procedure

Secondary Outcomes

  • Event Rates(30 days post procedure)
  • Functional improvement from baseline(30 days post procedure)
  • Acute device success(12 months post procedure)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Withdrawn
Not Applicable
Assessment of the St. Jude Medical Portico (TM) Re-sheathable Transapical Aortic Valve System (PORTICO TA EU)Aorta Valve StenosisNarrowing of the heart valve10046973
NL-OMON42009St. Jude Medical10
Completed
Not Applicable
Assessment of the St Jude Medical Portico Resheathable Aortic Valve System-Alternative AccessAortic Valve Stenosis
NCT03056573Abbott Medical Devices64
Completed
Not Applicable
Portico TAVI Implant With Transfemoral Delivery SystemSymptomatic Aortic Stenosis
NCT01493284Abbott Medical Devices222
Withdrawn
Not Applicable
Assessment of St Jude Medical Portico Re-sheathable Transapical Aortic Valve SystemSevere Symptomatic Aortic Stenosis
NCT01742598Abbott Medical Devices
Completed
Not Applicable
ASSESSMENT OF THE ST. JUDE MEDICAL PORTICO* TRANSCATHETER AORTIC VALVE IMPLANT (TAVI) AND THE SJM TAVI TRANSFEMORAL DELIVERY SYSTEMnarrowing of heart valveStenosis of Aortic valve10046973
NL-OMON41483St. Jude Medical15
Assessment of the St. Jude Medical... | Clinical Trial